AR018859A1 - Un compuesto derivado del indol, y una formulacion farmaceutica que lo comprende - Google Patents

Un compuesto derivado del indol, y una formulacion farmaceutica que lo comprende

Info

Publication number
AR018859A1
AR018859A1 ARP990102204A ARP990102204A AR018859A1 AR 018859 A1 AR018859 A1 AR 018859A1 AR P990102204 A ARP990102204 A AR P990102204A AR P990102204 A ARP990102204 A AR P990102204A AR 018859 A1 AR018859 A1 AR 018859A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
alkoxy
formula
compound
Prior art date
Application number
ARP990102204A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR018859A1 publication Critical patent/AR018859A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto derivado del indol de formula (I) en la cual n es 1 a 6, m es 1 o 2 y p es 1 o 2, R1 y R2, cada una de ellas, es hidrogeno,alquilo C1-4, alcoxi, C1-4 HO-alquilo C1-4 alcoxi C1-4alquilo C1-4, alquiltio C1-4, halo, fenilo opcionalmente sustituido, fenilo opcionalmente sustituido-alquilo C1-4 o R1 y R2, junto con el átomo de carbono al que están unidas forman un grupo cicloalquilo C3-6, >C=O,C=NOR donde R es hidrogeno o alquilo C1-4,R3, R4 y R6 cada una de ellas, es hidrogeno, halo, nitro, alquilo C1-4, alcoxi C1-4, alquilo C1-4 -CO-, donde m es 0, 1 o 2, RRN-SO2-, COOR-, CONRR,-NRR, -N(OR)COOR, -COR, -NHSO2R, donde R y R, cada una de ellas, es hidrogeno o alquilo C1-4, R6 y R7 cada una de ellas, es hidrogeno o alquilo C1-4, X es oxígeno o azufre, la línea punteada representa u doble enlace opcional, y el átomo de fluor está unido en la posicion 6 o 7; y sus sales. También seproporciona una formulacion farmacéutica que comprende el compuesto de formula (I). Elcompuesto de formula (I) y sus sales farmacéuticamente aceptables estánindicados en el tratamiento de los trastornos del sistema nervioso central. Son activos en las pruebas que indican modulacion serotonérgica.
ARP990102204A 1998-05-13 1999-05-11 Un compuesto derivado del indol, y una formulacion farmaceutica que lo comprende AR018859A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9810886.3A GB9810886D0 (en) 1998-05-13 1998-05-13 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
AR018859A1 true AR018859A1 (es) 2001-12-12

Family

ID=10832426

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102204A AR018859A1 (es) 1998-05-13 1999-05-11 Un compuesto derivado del indol, y una formulacion farmaceutica que lo comprende

Country Status (11)

Country Link
US (1) US6166040A (es)
EP (1) EP0963983A1 (es)
JP (1) JP2002514642A (es)
AR (1) AR018859A1 (es)
AU (1) AU3838499A (es)
CA (1) CA2330796A1 (es)
CO (1) CO5031250A1 (es)
GB (1) GB9810886D0 (es)
PE (1) PE20000467A1 (es)
SV (1) SV1999000059A (es)
WO (1) WO1999058525A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825413D0 (en) 1998-11-19 1999-01-13 Lilly Co Eli Pharmaceutical compounds
GB2362381A (en) * 2000-05-18 2001-11-21 Lilly Co Eli Pharmaceutically active indolyl-piperidines
US6844338B2 (en) 2000-05-18 2005-01-18 Eli Lilly And Company Piperidyindoles as serotonin receptor ligands
SI1294710T1 (en) * 2000-06-14 2005-10-31 H. Lundbeck A/S Indole derivatives useful for the treatment of cns disorders
AR028685A1 (es) * 2000-06-14 2003-05-21 Lundbeck & Co As H Derivados de indol
GB2370270A (en) * 2000-12-20 2002-06-26 Lilly Co Eli Pharmaceutical compounds
PT1392697E (pt) * 2001-03-14 2005-01-31 Wyeth Corp Antidepressivos derivados aza-heterociclilmetilo de 2,3- di-hidro-1,4-dioxino[2,3-f]quinolina
PL364580A1 (en) 2001-03-29 2004-12-13 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
US6861434B2 (en) * 2001-04-26 2005-03-01 Wyeth Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one
US6555560B2 (en) * 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
US6906206B2 (en) 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
US7135479B2 (en) * 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
CN100352820C (zh) * 2002-09-12 2007-12-05 惠氏公司 抗抑郁的杂环稠合的苯并二噁烷的氮杂环甲基衍生物
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
NZ553202A (en) * 2004-08-19 2010-12-24 Vertex Pharma Modulators of muscarinic receptors
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
AU2005309365B2 (en) * 2004-11-29 2011-10-06 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2006330866A1 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
NZ570497A (en) * 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
KR20080094964A (ko) 2006-02-22 2008-10-27 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제
US7858790B2 (en) * 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021375A2 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021545A2 (en) * 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP2207549A1 (en) * 2007-10-03 2010-07-21 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981881A (en) * 1975-08-14 1976-09-21 E. R. Squibb & Sons, Inc. 2-[(4-Phenyl-tetrahydropyridinyl)alkyl]-1H-isoindole-1,3(2H)-diones
JP2860688B2 (ja) * 1990-03-14 1999-02-24 第一製薬株式会社 インドール誘導体
FR2675801A1 (fr) * 1991-04-24 1992-10-30 Rhone Poulenc Rorer Sa Piperidines, leur preparation et les medicaments les contenant.
SE9103752D0 (sv) * 1991-12-18 1991-12-18 Astra Ab New compounds
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
TW421649B (en) * 1995-01-31 2001-02-11 Janssen Pharmaceutica Nv 4-(1H-indol-1yl)-1-piperidinyl derivatives
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives

Also Published As

Publication number Publication date
PE20000467A1 (es) 2000-06-05
AU3838499A (en) 1999-11-29
EP0963983A1 (en) 1999-12-15
WO1999058525A1 (en) 1999-11-18
CO5031250A1 (es) 2001-04-27
SV1999000059A (es) 2000-07-04
GB9810886D0 (en) 1998-07-22
CA2330796A1 (en) 1999-11-18
US6166040A (en) 2000-12-26
JP2002514642A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
AR018859A1 (es) Un compuesto derivado del indol, y una formulacion farmaceutica que lo comprende
LU92993I2 (fr) Briviact
AR016429A1 (es) Compuesto derivado de acido hidroxamico como inhibidores de metaloproteasa de matriz (mmp), composiciones farmaceuticas y formulaciones veterinarias, usopara la preparacion de composiciones y formulaciones, compuesto intermediario, procedimiento de preparacion del compuesto.
AR023971A1 (es) Derivados de 4,5,6,7-tetrahidroindazol, procedimiento para la preparacion de los mismos y su utilizacion como agentes antitumorales
ES2184280T3 (es) Compuestos de indol como inhibidores de cox-2'.
CO4440628A1 (es) Derivados de pirimidina condensados con un anillo heteroci- clico
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
AR025976A1 (es) Inhibidores de fab i.
ES2061502T3 (es) Nuevos n-heterociclos biciclicos puenteados.
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
AR056189A1 (es) Compuestos analogos de la camptotecina, procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos como agentes anticancer
DE10199016I1 (de) Indol derivate zur Behandlung von Migraene
PE20030707A1 (es) Agonistas muscarinicos
ES2172376B1 (es) Nuevos derivados de isoquinoleinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CO4930268A1 (es) BENZO[e]ISOINDOLES Y BENZO[h]ISOQUINOLINAS TRICICLICOS
ATE63306T1 (de) Indolderivate.
CO5170443A1 (es) Derivados de coclobuten-3,4-diona,su preparacion y su aplicacion terapeutica.
ECSP992951A (es) Compuestos farmaceuticos
AR048631A1 (es) Derivados de dialcoxi-imidazopiridinas, composiciones farmaceuticas que los contienen y usos,
ES2169909T3 (es) 5-hidroximetil-2-aminotetralinas como agentes cardiovasculares.
DE69914563D1 (de) Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe
AR022809A1 (es) Derivados de ciclobuten-3,4-diona, su preparacion y su aplicacion en terapeutica
NO20020475D0 (no) 2-aminotetralinderivater for terapi av glaukom
AR015154A1 (es) Un compuesto derivado del indol fluoro-sustituido, su uso y una formulacion farmaceutica que lo comprende